Shawn Aaron profile picture

Contact Information

Shawn Aaron, MD, FRCPC
613-737-8899 ext. 74729
saaron@ohri.ca

Dr. Shawn Aaron
Division Director- Respirology
Professor, University of Ottawa
501 Smyth Road
Ottawa, ON
K1H 8L6
Canada

Phone: 613-739-6636
Fax: 613-739-6807

Publications

Selected Publications

140 career peer-reviewed research publications. 69 in the past 5 years.

Aaron SD, Vandemheen K, FitzGerald JM, et al.  Reevaluation of Diagnosis in Adults with Physician-Diagnosed Asthma.  JAMA 317(3):269-279, 2017.

Aaron SD, Vandemheen KL, Ramotar K, et al. Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA 304 (19): 2145-2153, 2010.

Aaron SD, Vandemheen K, Boulet LP, et al. Over-diagnosis of asthma in obese and non-obese adults. CMAJ 179(11): 1121-1131, 2008.

Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. Tiotropium in combination with placebo, salmeterol or fluticasone/salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Annals of Internal Medicine 146 (8):545-555, 2007.

Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, Berthiaume Y, Brown N, Wilcox P, Yozghatlian V, Bye P, Bell S, Chan F, Rose B, Jeanneret A, Stephenson A, Noseworthy M, Freitag A, Paterson N, Doucette S, Harbour C, Ruel M, MacDonald M. Combination Antibiotic Susceptibility Testing to Treat Exacerbations of Cystic Fibrosis Associated with Multi-Resistant Bacteria: A Randomized, Double-Blind, Controlled Clinical Trial. The Lancet 366: 463-71, 2005.

Aaron SD, Vandemheen K, Hebert P, Dales R, Stiell I, Ahuja J, Dickinson G, Brison R, Rowe B, Dreyer J, Yetisir E, Cass D, Wells G. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. The New England Journal of Medicine 348, 2618-25, 2003. 




    1)    Filho F, Ra S, Mattman A, Schellenberg R, Aaron SD (co-senior author), Reed R (co-senior author), Sin D (co-senior author).   Serum Immunoglobulin G and Risk of Exacerbations and Hospitalizations in COPD.  J Allergy Clin Immun, 2017 Apr 26. pii: S0091-6749(17)30675-9. doi: 10.1016/j.jaci.2017.01.046, in press.  

2)    Kahn SR, Akaberi A, Granton JT, Anderson DR, Wells PS, Rodger MA, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Dennie C, Rush C, Hernandez P, Aaron SD, Hirsch AM.  Quality of Life, Dyspnea and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort Study.  Am J Med, Apr 8. pii: S0002-9343(17)30361-3. doi: 10.1016/j.amjmed.2017.03.033, 2017.  

3)    Ma K, Kahn SR, Hirsch AM, Akaberi A, Anderson DR, Wells PS, Rodger M, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Dennie C, Rush C, Hernandez P, Aaron SD, Granton JT.  N-terminal of prohormone brain natriuretic peptide predicts functional limitation one year following pulmonary embolism: Results from the ELOPE study.  Thromb Res. Mar 8;153:47-49. doi: 10.1016/j.thromres.2017.03.005, 2017, in press.  

4)    Kendzerska T, Sadatsafavi M, Aaron SD, To T, Lougheed D, FitzGerald JM, Gershon AS.  Concurrent Physician-Diagnosed Asthma and Chronic Obstructive Pulmonary Disease: A Population Study of Prevalence, Incidence and Mortality.  PLOS One, Mar 16;12(3):e0173830. doi: 10.1371/journal.pone.0173830, 2017.  

5)    Stephenson A, Sykes J, Berthiaume Y, Singer L, Aaron SD, Whitmore G, Stanojevic S.  .A Prediction Model for Post-Transplant Survival Using Pre-Transplant Clinical Characteristics in Adults with Cystic Fibrosis.  Clinical Transplantation, doi: 10.1111/ctr.12950, in press.  

6)    Aaron SD, Tan W, Bourbeau J, Sin D, Loves R, MacNeil J, Whitmore GA.  Diagnostic Instability and Reversals of COPD Diagnosis in Subjects with Mild to Moderate Airflow Obstruction.  AmJRCCM, DOI: 10.1164/rccm.201612-2531OC, in press.  

7)    Aaron SD, Vandemheen K, FitzGerald JM, et al.  Reevaluation of Diagnosis in Adults with Physician-Diagnosed Asthma.  JAMA 317(3):269-279, 2017.  

8)    Kahn SR, Hirsch AM, Akaberi A, Anderson DR, Aaron SD, Granton TJ.  Functional and exercise limitations after a first episode of pulmonary embolism: Results of the ELOPE prospective cohort study. Chest 2016 Dec 5. pii: S0012-3692(16)62555-2, in press.  

9)    Lacasse Y, Bernard S, Sériès F, Nguyen VH, Bourbeau J, Aaron SD, Maltais F;  Multi-center, randomized, placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease: a study protocol for the INOX trial. BMC Pulm Med Jan 9;17(1):8. doi: 10.1186/s12890-016-0343-9, 2017.  

10) Bourbeau J, Aaron SD, Barnes N, Davis K, Lacasse Y, Nadeau G.  Evaluating the risk of pneumonia with inhaled corticosteroids in COPD: Retrospective database studies have their limitations.  Respiratory Med, 123; 94-97, 2017.  

11) Stiell IG, Perry J, Clement C, Brison R, Rowe B, Aaron SD, McRae A et al.  Prospective and explicit clinical validation of the Ottawa Heart Failure Risk Scale with and without use of quantitative NT-proBNP.  Acad Emerg Med 24; 316-327, 2017.  

12) Gershon A, Mecredy G, Croxford R, To T, Stanbrooke M, Aaron SD.  Outcomes of patients with chronic obstructive pulmonary disease diagnosed with or without pulmonary function testing.  CMAJ, 189(14):E530-E538, 2017.  

13) Tavakoli H, FitzGerald JM, Chen W, Lynd L, Kendzerska T, Aaron S, Gershon A, Marra C, Sadatsafavi M.  Ten-year trends in direct costs of asthma: a population-based study.  Allergy, 72(2):291-299, 2017.  

14) Kendzerska T, To T, Aaron SD, et al. The Impact of a History of Asthma on Long-Term Outcomes of People with Newly Diagnosed Chronic Obstructive Pulmonary Disease: A Population Study.  J Allergy Clin Immunol, 139(3):835-843, 2017.  

15) Aaron SD, Gershon A, Gao C, Yang J, Whitmore GA.  Influence of Country-Level Differences on COPD Prevalence.  Int J COPD, 11: 2305-2313, 2016.   

16) MacNeil J, Loves R, Aaron SD (senior author).  Addressing the misdiagnosis of asthma in adults:  where does it go wrong?  Expert Review of Resp Med, Oct 8:1-12, 2016.  

17) Tan WC, Hague CJ, Leipsic J, Bourbeau J, Zheng L, Li PZ, Sin DD, Coxson HO, Kirby M, Hogg JC, Raju R, Road J, O'Donnell DE, Maltais F, Hernandez P, Cowie R, Chapman KR, Marciniuk DD, FitzGerald JM, Aaron SD.  Findings on Thoracic Computed Tomography Scans and Respiratory Outcomes in Persons with and without Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.  PLoS One Nov 18;11(11):e0166745, 2016  

18) Gupta N, Pinto L, Benedetti A, Li P, Tan W, Aaron SD, Chapman K, et al. The COPD Assessment Test: Can it discriminate across COPD subpopulations?  Chest 150(5): 1069-1079, 2016.  

19) Gershon A, Hwee J, Chapman K, Aaron SD, O’Donnell D, et al.  Factors Associated with Undiagnosed and Overdiagnosed COPD.  European Resp J 48(2):561-4, 2016.  

20) Leung JM, Hollander Z, Chen V, Dai D, Tebbutt S, Aaron SD, et al.  COPD Exacerbation Biomarkers Validated Using Multiple Reaction Monitoring Mass Spectrometry.  PLOS ONE DOI:10.1371/journal.pone.0161129, August 15, 2016.  

21) Huus KE, Joseph J, Zhang L, Aaron SD, Mah TF, and Sad S.  Clinical isolates of Pseudomonas aeruginosa from chronically infected cystic fibrosis patients fail to activate the inflammasome during both stable infection and pulmonary exacerbation.  J Immunology, Apr 1;196(7):3097-3108, 2016.   

22) Pakhale S, Baron J, Armstrong M, Tasca G, Gaudet E,  Aaron SD, Cameron W, Balfour L. Lost in translation? How adults living with Cystic Fibrosis understand treatment recommendations from their healthcare providers, and the impact on adherence to therapy.  Patient Education and Counseling 99(8):1319-24, 2016.  

 23) Labonté LE, Tan WC, Li Z, Mancino P, Aaron SD, et al.  Undiagnosed COPD Contributes to the Burden of Health Care Utilization: Data from the CanCOLD Study. Am J Resp Crit Care Med, 194(3):285-98, 2016.  

 24) Flume P, VanDevanter D, Morgan E, Dudley M, Loutit JS, Aaron SD, Conrad D, Geller DE, Elborn JS.  A Phase 3, Multi-center, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levofloxacin Inhalation Solution (APT-1026) in Stable Cystic Fibrosis Patients.  Journal of Cystic Fibrosis, 15(4):495-502, 2016.  

25) Sadatsafavi M, Tavakoli H, Kendzerska T, Gershon A, To T, Aaron SD, FitzGerald JM.  History of asthma in patients with chronic obstructive pulmonary disease: a comparative study of economic burden.  Annals of the American Thoracic Society, 13(2):188-96, 2016.  

26) De Matteis S, Iridoy A, Aaron SD, Swann A, Cullinan P.  A new spirometry-based algorithm to predict occupational pulmonary restrictive impairment.  Occupational Med J, 2016 Jan;66(1):50-3.  

27) Chin M, Earlam K, Aaron SD (senior author).  Survival in cystic fibrosis; Trends, Clinical Factors, and Prediction Models.  Pediatric Allergy, Immunology and Pulmonology, 28(4): 244-249, 2015.  

28) Cowan J, Gaudet L, Mulpuru S, Corrales-Medina V, Hawken S, Cameron C, Aaron SD, Cameron DW.  A Retrospective Longitudinal Within-Subject Risk Interval Analysis of Immunoglobulin Treatment for Recurrent Acute Exacerbation of Chronic Obstructive Pulmonary Disease.  PLOS ONE DOI:10.1371/journal.pone.0142205, 2015.  

29) Freschi L, Jeukens J, Kukavica-Ibrulj I, Boyle B, Aaron SD, et al.  Clinical utilization of genomics data produced by the international Pseudomonas aeruginosa consortium.  Frontiers in Microbiology 6:1036. doi: 10.3389/fmicb.2015.01036, 2015.  

30) Tan W, Bourbeau J, Hernandez P, Chapman K, Aaron SD.  Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study.  Thorax, 70(9):822-829, 2015.  

 31) Mulpuru S (master’s student), Aaron SD (senior author), Ronksley P, Lawrence N, Forster AJ.  Hospital Resource Utilization and Patient Outcomes Associated with Respiratory Viral Testing in Hospitalized Patients. Emerging Infectious Diseases 21(8): 1366-71, 2015.  

 32) Stephenson AL,  Sykes J, Berthiaume Y, Singer LG, Aaron SD, Whitmore GA, Stanojevic S.  Clinical and Demographic Factors Associated with Post-lung Transplantation Survival In Individuals with Cystic Fibrosis: A National Cohort Study.  J Heart Lung Transplant, 34(9):1139-45, 2015.  

33) Alvarez G, Van Dyk D, Desjardins M, Yasseen A, Aaron SD, Cameron DW, et al.  The feasibility, accuracy and impact of Xpert® MTB/RIF testing in a remote Aboriginal community in Canada.  Chest, 148(3):767-73, 2015.  

34) Pakhale S, Baron J, Armstrong M, Tasca G, Gaudet E, Aaron SD, Cameron W, Balfour L.  A cross-sectional study of the psychological needs of adults living with cystic fibrosis.  PLoS ONE, Jun 23;10(6):e0127944. doi: 10.1371, 2015.  


35) Stacey D, Vandemheen K, Henessey R, Aaron SD (senior author).  Implementation of a cystic fibrosis lung transplant referral patient decision aid in routine clinical practice: An observational study.  Implementation Science 7;10(1):17 DOI 10.1186/s13012-015-0206-4, 2015.  

36) Pakhale S, Baron J, Dent R, Vandemheen K, Aaron SD (senior author).  Effects of weight loss on airway responsiveness in obese asthmatics: Does weight loss lead to reversibility of asthma?  Chest, 147(6):1582-90, 2015.  

37) Stephenson A, Tom M, Berthiaume Y, Singer L, Aaron SD, Whitmore GA, Stanojevic S.  A Contemporary Survival Analysis of Individuals with Cystic Fibrosis: A Cohort Study.  Eur Respir J 45:3, 670-679, 2015.      

38) Aaron SD, Stephenson A, Cameron DW, Whitmore GA.  A statistical model to predict one year risk of death in patients with cystic fibrosis.  J Clin Epidemiol 68(11):1336-1345, 2015.  

39) Elborn J, Gelber D, Conrad D, Aaron SD, et al.  A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of Levofloxacin Inhalation Solution (APT-1026) versus Tobramycin Inhalation Solution in Stable Cystic Fibrosis Patients.  Journal of Cystic Fibrosis, 14: 507-514, 2015.  

40) Chin M (respirology resident), De Zoysa M, Slinger R, Aaron SD (senior author).  Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations.  Journal of Cystic Fibrosis, 14: 482-489, 2015.  

41) Srour N, Chaparro C, Vandemheen K, Singer L, Keshavjee S, Aaron SD (senior author).  Impact of infection with transmissible strains of Pseudomonas aeruginosa on lung transplantation outcomes in patients with cystic fibrosis.  J Heart Lung Transplantation, 34(4):588-93, 2015.  

42) Rowe B, Villa-Roel C, Majumdar S, Abu-Laban R, Aaron SD, et al.  Rates and Correlates of Relapse Following Emergency Department Discharge for Acute Asthma: A Canadian 20-Site Prospective Cohort Study.  Chest, 147(1):140-9, 2015.  

43) Alvarez G, Van Dyk D, Davies N, Aaron SD, Cameron DW, et al.  The feasibility of the Interferon Gamma Release Assay and predictors of discordance with the tuberculin skin test for the diagnosis of latent tuberculosis infection in a remote Aboriginal community.  PLOS One, 2014 Nov 11;9(11):e111986. doi: 10.1371/journal.pone.0111986.

44) Aaron SD.  State of the Art- Management and Prevention of Exacerbations of COPD.  BMJ ; 349: g5237, doi: 10.1136/bmjg5237, 2014.  

45) Criner, G. J., Connett, J. Aaron, SD, Albert, R., Bailey, W., Casaburi, R., Cooper, A., Curtis, J.L., Dransfield, M., Han, M., Make, B., Marchetti, N., Martinez, F. J., Niewoehner, D., Scanlon, P., Sciurba, F., Scharf, S., Sin, D., Voelker, H., Washko, G., Woodruff, P., and Lazarus, S.  Simvastatin for the Prevention of Exacerbations in Moderate to Severe COPD.  New England Journal of Medicine 370 (23): 2201-2210, 2014.  

46) Balfour L, Armstrong M, Holly C, Gaudet E, Aaron SD, Tasca G, Cameron W, Pakhale S.  Development and psychometric validation of a cystic fibrosis knowledge scale.  Respirology 19(8):1209-14, 2014.  

47) Alvarez G, VanDyk DD, Aaron SD, Cameron DW, et al.  TAIMA (Stop) TB: The impact of a multifaceted TB awareness and door-to-door campaign in residential areas of high risk for TB in Iqaluit, Nunavut.  PLoS ONE 9(7): e100975, 2014. doi:10.1371/journal.pone.0100975.  

48) Sadatsafavi, M, Marra C, Aaron SD, Brian S.  Incorporating external evidence in trial-based cost-effectiveness analysis: the use of resampling methods.  Trials, 15(1):201, 2014.  

49) Pakhale S, Armstrong M, Holly C, Edjoc R, Gaudet E, Aaron SD, Tasca G, Cameron W, Balfour L.  Assessment of Stigma in Patients with Cystic Fibrosis. BMC Pulmonary Medicine, 14:76, DOI: 10.1186/1471-2466-14-76, 2014.

50) Bafadhel M, Davies L, Calverley P, Aaron SD, Brightling C, Pavord I.  Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis.  European Resp J, 44:789-791, 2014.  

51) Jeukens J, Boyle B, Kukavica-Ibrulj I, Ouellet M, Aaron SD, et al.  Comparative Genomics of Isolates of a Pseudomonas aeruginosa Epidemic Strain Associated with Chronic Lung Infections of Cystic Fibrosis Patients.  PLoS ONE, 9(2): e87611, 2014.  

52) Tan W, Bourbeau J, Hernandez P, Chapman K, Aaron SD.  Exacerbation-Like Respiratory Symptoms in Individuals without COPD:  Results from a Population Study.  Thorax, 69(8):709-17, 2014.   53) Stiell I, Clement C, Aaron SD, et al.  Clinical Characteristics Associated with Adverse Events in Patients with Exacerbation of Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study.  CMAJ, 186(6):E193-204, 2014.  

Listings from The Ottawa Hospital Library

This lists the 12 most recent publications in The Ottawa Hospital's Library database from this researcher.This database only starts tracking a researcher's publications once they start working at the Ottawa Hospital Research Institute.

Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, Kerem E, Bell SC, Loutit JS, Dudley MN, Morgan EE, VanDevanter DR, Flume PA., 2015 2015-07-01, A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients., J CYST FIBROS, 14, 4, 507-514

More publications may be available in The Ottawa Hospital Library database.

PubMed Listings

For more publications use this PubMed ID link.